Arteriovenous Fistula, Arteriovenous Graft, Brain Natriuretic Peptide, Left Ventricular Hypertrophy
Conditions
Keywords
Hemodialysis, Arteriovenous Fistula, Arteriovenous Graft, Left Ventricular Hypertrophy, Brain Natriuretic Peptide
Brief summary
The purpose of this study is to determine if the creation of a fistula or a graft plays a role in the development of heart disease for patients undergoing hemodialysis
Detailed description
Patients with end stage renal disease are at 18-20 times greater risk of dying from cardiovascular disease as the general population. Both traditional and non-traditional cardiovascular risk factors are thought to be important. Of the non-tradtional cardiovascular risk factors, creation of an arteriovenous fistula or graft for the purposes of a blood access for hemodialysis may contribute to an elevation in BNP and left ventricular hypertrophy - both factors that have been associated with an increased risk of mortality Prior to access creation and at one month and one year post access creation - samples for BNP will be collected Prior to access creation and at one year post access creation - echocardiography will be performed
Interventions
None listed
Sponsors
The Kidney Foundation of Canada
Ottawa Hospital Research Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1)Hemodialysis 2)high risk for heart failure (DM, age>50, and/or systolic dysfunction) 3) first arteriovenous fistula/graft 4) informed consent 5) technically adequate echocardiogram 6) stable hgb(>100) 7) stable mineral metabolism (normal calcium, phosphate <2.1mmol/L, PTH>50pmol/L)
Exclusion criteria
1)Expected survival <1 year 2) Expected to get a living donor transplant in one year 3)primary access failure 4) ARF
Countries
Canada
Outcome results
None listed